Esophageal Cancer Pipeline Assessment, 2024 | In-depth Insights into the Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Clinical Trials, and Treatment Outlook | Oncolys BioPharma Inc, Genentech

The Esophageal Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Esophageal Cancer Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Esophageal Cancer Market.

Some of the key takeaways from the Esophageal Cancer Pipeline Report:

• Companies across the globe are diligently working toward developing novel Esophageal Cancer treatment therapies with a considerable amount of success over the years. 
• Esophageal Cancer companies working in the treatment market are CDR-Life Inc., Merck KGaA, Apexigen, Genmab, Oncolys BioPharma Inc, Genentech, Onco Therapy Science, Inc., Shionogi & Co., Ltd., CStone Pharmaceuticals, Celgene, MedImmune, Seagen, Apexigen,Janssen Research & Development, MacroGenics, Adlai Nortye, and others, are developing therapies for the Esophageal Cancer treatment 

• Emerging Esophageal Cancer therapies in the different phases of clinical trials are- CDR404, M1231, Sotigalimab, Amivantamab, Telomelysin, Tiragolumab, S-588410, CS1001, Durvalumab, Tucatinib, APX 005M, Erdafitinib, Margetuximab, AN-0025, and others are expected to have a significant impact on the Esophageal Cancer market in the coming years.   
• In March 2024, BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global leader in oncology, has announced today that the U.S. Food and Drug Administration (FDA) has granted approval for TEVIMBRA® (tislelizumab-jsgr) as a standalone treatment for adult patients suffering from unresectable or metastatic esophageal squamous cell carcinoma (ESCC) who have previously undergone systemic chemotherapy that did not involve a PD-(L)1 inhibitor. TEVIMBRA is expected to be accessible in the U.S. market during the latter half of 2024.
• In September 2022, Integral Molecular has granted CARTEXELL a license for a series of monoclonal antibodies (MAbs) to facilitate the development of CAR-T cell therapies utilizing Integral Molecular’s Claudin 18.2 (CLDN18.2) MAbs. The agreement entails an exclusive global license for CARTEXELL to utilize the set of CLND18.2 MAbs, known for their high specificity, high affinity, and complete humanization, for the creation of CAR-T cell therapies targeting solid tumors such as gastric, lung, pancreatic, and esophageal cancers. CARTEXELL assumes sole responsibility for all research, development, and commercial endeavors as per the terms of the agreement
• In August 2022, BeiGene disclosed that the China National Medical Products Administration’s (NMPA) Center for Drug Evaluation (CDE) has approved a supplemental biologics license application (sBLA) for tislelizumab. The application pertains to the use of tislelizumab in combination with chemotherapy for the initial treatment of patients diagnosed with unresectable locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC).
• In May 2022, Shanghai Junshi Biosciences Co., Ltd, revealed that the China National Medical Products Administration (NMPA) sanctioned the supplemental new drug application (sNDA) for toripalimab in conjunction with paclitaxel and cisplatin. This approval is for the initial treatment of patients facing unresectable locally advanced/recurrent or distant metastatic esophageal squamous cell carcinoma (ESCC). The NMPA accepted the sNDA in July 2021, marking toripalimab’s fifth approved indication in China. This decision is expected to significantly benefit Chinese patients coping with advanced ESCC.
• In May 2022, Bristol Myers Squibb reported the U.S. Food and Drug Administration’s (FDA) approval for both Opdivo (nivolumab) in combination with fluoropyrimidine- and platinum-containing chemotherapy and Opdivo with Yervoy (ipilimumab) as the initial treatment for adult patients dealing with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC), irrespective of their PD-L1 status. These approvals are grounded on the Phase III CheckMate -648 trial, which investigated Opdivo combined with chemotherapy (n=321) and Opdivo plus Yervoy (n=325) in comparison to chemotherapy alone (n=324). This trial represents the most extensive Phase III study in first-line ESCC immunotherapy.

Esophageal Cancer Overview

The development of cancer cells in the esophagus, a long, tube-like tissue that connects the throat and the stomach, results in esophageal cancer. As a component of the upper digestive system, the esophagus transports food that has been swallowed to the stomach. Squamous cell carcinoma and adenocarcinoma are the two primary kinds.

Get a Free Sample PDF Report to know more about Esophageal Cancer Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/esophageal-cancer-pipeline-insight

Emerging Esophageal Cancer Drugs Under Different Phases of Clinical Development Include:

• CDR404: CDR-Life Inc.
• M1231: Merck KGaA
• Sotigalimab: Apexigen
• Amivantamab: Genmab
• Telomelysin: Oncolys BioPharma Inc
• Tiragolumab: Genentech
• S-588410: Onco Therapy Science, Inc. /Shionogi & Co., Ltd.
• CS1001: CStone Pharmaceuticals
• Durvalumab: Celgene/MedImmune
• Tucatinib: Seagen
• APX 005M: Apexigen
• Erdafitinib: Janssen Research & Development, LLC
• Margetuximab: MacroGenics
• AN-0025: Adlai Nortye

Esophageal Cancer Route of Administration

Esophageal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Esophageal Cancer Molecule Type

Esophageal Cancer Products have been categorized under various Molecule types, such as

• Oligonucleotide
• Peptide
• Small molecule

Esophageal Cancer Pipeline Therapeutics Assessment

• Esophageal Cancer Assessment by Product Type
• Esophageal Cancer By Stage and Product Type
• Esophageal Cancer Assessment by Route of Administration
• Esophageal Cancer By Stage and Route of Administration
• Esophageal Cancer Assessment by Molecule Type
• Esophageal Cancer by Stage and Molecule Type

DelveInsight’s Esophageal Cancer Report covers around 80+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Esophageal Cancer product details are provided in the report. Download the Esophageal Cancer pipeline report to learn more about the emerging Esophageal Cancer therapies

Some of the key companies in the Esophageal Cancer Therapeutics Market include:

Key companies developing therapies for Esophageal Cancer are – Novartis Pharmaceuticals, Sanofi, Seagen Inc., Rapa Therapeutics LLC, Incyte Corporation, Atreca, Inc., Exelixis, Bayer, BeiGene, Lyell Immunopharma, Sichuan Baili Pharmaceutical, AP Biosciences.,Leap Therapeutics, Inc., Adlai Nortye Biopharma Co., Ltd., Athenex, Inc., Pfizer, Genentech, Hangzhou Neoantigen Therapeutics, Janssen Pharmaceutical, Curis, Inc.,Merck KGaA, Apexigen, Inc,Shenzhen Hornetcorn Bio-technology Company, LTD, MacroGenics, Bristol-Myers Squibb, Integral Molecular, CARTEXELL, EMD Serono, and others.

Esophageal Cancer Pipeline Analysis:

The Esophageal Cancer pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Esophageal Cancer with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Esophageal Cancer Treatment.
• Esophageal Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Esophageal Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Esophageal Cancer market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Esophageal Cancer drugs and therapies

Esophageal Cancer Pipeline Market Drivers

• Increase in the number of cases of Esophageal Cancer, increasing research and development and launches of novel products by key players are some of the important factors that are fueling the Esophageal Cancer Market.

Esophageal Cancer Pipeline Market Barriers

• However, high cost of therapy for the treatment of esophageal cancer, side effects associated with the current treatment options and other factors are creating obstacles in the Esophageal Cancer Market growth.

Scope of Esophageal Cancer Pipeline Drug Insight    

• Coverage: Global
• Key Esophageal Cancer Companies: CDR-Life Inc., Merck KGaA, Apexigen, Genmab, Oncolys BioPharma Inc, Genentech, Onco Therapy Science, Inc., Shionogi & Co., Ltd., CStone Pharmaceuticals, Celgene, MedImmune, Seagen, Apexigen,Janssen Research & Development, MacroGenics, Adlai Nortye, and others
• Key Esophageal Cancer Therapies: CDR404, M1231, Sotigalimab, Amivantamab, Telomelysin, Tiragolumab, S-588410, CS1001, Durvalumab, Tucatinib, APX 005M, Erdafitinib, Margetuximab, AN-0025, and others
• Esophageal Cancer Therapeutic Assessment: Esophageal Cancer current marketed and Esophageal Cancer emerging therapies
• Esophageal Cancer Market Dynamics: Esophageal Cancer market drivers and Esophageal Cancer market barriers 

Request for Sample PDF Report for Esophageal Cancer Pipeline Assessment and clinical trials

Table of Contents

1. Esophageal Cancer Report Introduction

2. Esophageal Cancer Executive Summary

3. Esophageal Cancer Overview

4. Esophageal Cancer- Analytical Perspective In-depth Commercial Assessment

5. Esophageal Cancer Pipeline Therapeutics

6. Esophageal Cancer Late Stage Products (Phase II/III)

7. Esophageal Cancer Mid Stage Products (Phase II)

8. Esophageal Cancer Early Stage Products (Phase I)

9. Esophageal Cancer Preclinical Stage Products

10. Esophageal Cancer Therapeutics Assessment

11. Esophageal Cancer Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Esophageal Cancer Key Companies

14. Esophageal Cancer Key Products

15. Esophageal Cancer Unmet Needs

16 . Esophageal Cancer Market Drivers and Barriers

17. Esophageal Cancer Future Perspectives and Conclusion

18. Esophageal Cancer Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/